AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00002548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 1.5 g/m2 in 100 ml of D5W, IV intravenously over 1 hour every 3 hour x 3 (total dose 4.5 g/m2)
Study NCT00002548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 40 mg/day PO or IVPB days 1-4, 9-12, 17-20 q 5 weeks
Study NCT00002548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Description: 10 mg/m2/day continuous 1 - 4 q 5 weeks
Study NCT00002548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: 10 mg/m2/day continuous 1 - 4 q 5 weeks
Study NCT00002548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: melphalan
Description: 140 mg/m2 is given IV within 30 minutes of constitution on Day -5
Study NCT00002548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: 140 mg/m2 is given IV within 30 minutes of constitution on Day -5
Study NCT00002548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: 40 mg/m2 PO days 1-7 q 35 days
Study NCT00002548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 40 mg/m2 PO days 1-7 q 35 days
Study NCT01664858 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: X-Ray coronary angiography
Description: X-Ray coronary angiography
Study NCT02983058 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: PET/SPECT Scan
Description: PET scan will be performed on a mCT scanner
Study NCT00002548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate
Description: 0.5 mg/day continuous 1 - 4 q 5 weeks
Study NCT00002548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: 0.5 mg/day continuous 1 - 4 q 5 weeks
Study NCT00002548 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Description: day 0
Study NCT00002548 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous bone marrow transplantation
Description: day 0
Study NCT00002548 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: peripheral blood stem cell transplantation
Description: day 0
Study NCT00002548 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: day 0
Study NCT00002548 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: administered in fractionated doses of 150 cGy, 6 - 10 hours apart bid, on Days -4, -3, -2, and -1 (Total 1,200 cGy)
Study NCT00506454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipidose
Description: Over the course of 2 weeks, immediately following subject's three (Monday/Wednesday/Friday (M/W/F)) normal dialysis treatments, based on subject's current weight, subject will receive 1.5 mL/kg of Lipidose over a 2-hour period.
Study NCT00506454 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Over the course of 2 weeks, immediately following subject's three (M/W/F) normal dialysis treatments, based on subject's current weight, subject will receive 1.5 mL/kg of placebo over a 2-hour period.
Study NCT02855658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SS-1
Description: The patients will be divided into two groups (A and B) at random and all of them keep the routine treatment in the rheumatology OPD. Group A patients will receive 12 weeks SS-1 treatment first, and then stop the SS-1 for 4 weeks for wash-out phase, and then receive 12 weeks placebo treatment. Group B patients receive 12 weeks placebo first, and then stop the placebo treatment for 4 weeks for wash-out phase, and then receive 12 weeks SS-1 treatment. SS-1 is composed of 3 traditional Chinese herbal formula: Gan-Lu-Yin, Sang-Ju-Yin and Xuefu-Zhuyu-Decoction with the ratio of 2:1:1. The placebo is composed with corn starch, pigment and minimal dose of 1% SS-1. Patients in both groups take 6 gram of SS-1/Placebo three times per day.
Study NCT02855658 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is composed of corn starch, pigment and minimal dose of 1% SS-1. Patients take 6 gram of experiment medicine three times per day.
Study NCT02869672 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tiantan Biology ACYW135 meningococcal polysaccharide vaccine
Description: Tiantan Biology ACYW135 meningococcal polysaccharide vaccine, intramuscular injection, 0.5 ml
Study NCT02869672 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hualan Biology ACYW135 meningococcal polysaccharide vaccine
Description: Hualan Biology ACYW135 meningococcal polysaccharide vaccine, intramuscular injection, 0.5 ml
Study NCT01828840 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epidural morphine via PCEA
Study NCT01828840 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epidural fentanyl via PCEA
Study NCT01828840 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epidural methadone via PCEA
Study NCT01828840 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous morphine via PCA
Study NCT03040128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: high-dose, intravenous minocycline
Study NCT03040128 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline infusion
Study NCT05214430 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3 months exclusive enteral nutrition after surgery
Description: patients underwent intestinal resection and anastomosis in this arm will given over 3 months exclusive enteral nutrition,and free diet after 3 months.
Study NCT00414076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: 2.5 mg Tablet By Mouth Daily for 12 Weeks.
Study NCT00652171 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: Lamotrigine was added to the ongoing antidepressant. The doses were titrated to 200mg/day.
Study NCT02983058 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MRI Scan
Description: Structural MRI will be obtained to permit co-registration of PET images
Study NCT00652171 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Amide
Description: Capsule of amide were given to this group of patients. They continued the ongoing antidepressants.
Study NCT00948077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifater and EMB
Description: The main difference between Treatment A and Treatment B is the time of taking drugs, so the intervention of this study belongs to a behavioral intervention.~The patients assigned randomly the Arm Treatment A on the fifth day will be switched to the Arm Treatment B on the sixth day. On the other hand, the patients assigned randomly the Arm Treatment B on the fifth day will be switched to the Arm Treatment A on the sixth day. The flow of intervention is drawn as below.~Treatment A (5th day) ---> Treatment B (6th day) ; Treatment B (5th day) ---> Treatment A (6th day)
Study NCT00948077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifater and EMB
Description: The main difference between Treatment A and Treatment B is the time of taking drugs, so the intervention of this study belongs to a behavioral intervention.~The patients assigned randomly the Arm Treatment A on the fifth day will be switched to the Arm Treatment B on the sixth day. On the other hand, the patients assigned randomly the Arm Treatment B on the fifth day will be switched to the Arm Treatment A on the sixth day. The flow of intervention is drawn as below.~Treatment A (5th day) ---> Treatment B (6th day) ; Treatment B (5th day) ---> Treatment A (6th day)
Study NCT00959907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BOTULINUM TOXIN TYPE-A
Description: On Visit 1 (Day 0):~Botulinum toxin A (Dysport® and Botox®) will be administered according to an equivalence ratio of 2:1. Both reconstituted in the same volume per point, injected in the forehead determined site.~* Dysport®: 4 units will be injected in the left or right forehead side.~* Botox® : 2 units will be injected in the left or right forehead side.(opposite side of dysport injection)
Study NCT01991483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2928057
Description: Administered intravenously
Study NCT01991483 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered intravenously
Study NCT04635202 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise training on elliptical device
Description: This group (n=30) will receive aerobic training on an elliptical trainer for 16 weeks (3 sessions per week). The session will start with 5 minutes warming up at 50 % of maximal heart rate (MHR), 20-minute continuous ET at 70% of MHR, 12 minutes (4×3) intervals at 90% of MHR with a 3-minute active recovery at 70% of MHR between intervals, and finally 5-minute cool-down period at 50% of MHR
Study NCT04635202 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: group B (control group)
Description: this group will receive general advises on maintaining physical activities for 16 weeks without any additional supervised training
Study NCT02799589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: 1mcg/kg over 1 min followed by an infusion (0.05-0.5 mcg/kg/min)
Study NCT01837966 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lavender oil
Description: 2 drops for aromatherapy
Study NCT01837966 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 drops unscented mineral oil for aromatherapy
Study NCT02931175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACTH gel
Description: Starting at month 6, retreatment will be offered to study subjects who have demonstrated any level of response during the first 6 months and who meet any of these Retreatment Criteria listed below. Patients receiving retreatment will receive the dose that was assigned to them at randomization.
Study NCT01187836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRV120027
Description: Dose range (starting at 0.1 mcg/kg/min) of TRV120027 administered for 14 hours.
Study NCT01187836 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered for 14 hours.
Study NCT00369967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NuvaRing
Description: Initiation of NuvaRing for contraception
Study NCT00369967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NuvaRing
Description: Initiation of NuvaRing for contraception
Study NCT01675258 — intervention group
Intervention type: OTHER
Intervention: Salivary samples
Description: Each participant will give a sample of saliva through spitting for 10 minutes in a sterile tube.
Study NCT01558986 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: Patients received intravenous cefazolin 1 gram within 30 minutes prior to skin incision;
Study NCT01558986 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sterile water
Description: Patients received sterile water only within 30 minutes prior to skin incision
Study NCT00708188 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multidetector raw CT
Description: Multidetector raw CT
Study NCT00480077 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Programming (CRT-D, ICD OptiVol® and Cardiac Compass® )
Description: OptiVol® Fluid status Monitoring with Cardiac Compass
Study NCT00480077 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Programming (CRT-D, ICD OptiVol® and Cardiac Compass® )
Description: OptiVol® Fluid status Monitoring with Cardiac Compass
Study NCT04626180 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extubation
Description: Extubation is the removal of an endotracheal tube (ETT), which is the last step in liberating a patient from the mechanical ventilator.
Study NCT04626180 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extubation
Description: Extubation is the removal of an endotracheal tube (ETT), which is the last step in liberating a patient from the mechanical ventilator.
Study NCT04626180 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual Hyperinflation
Description: Providing a larger tidal volume than baseline tidal volume to the patient and using a tidal volume which is 50% greater than that delivered by the ventilator
Study NCT02799589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: 1mcg/kg over 10 mins followed by and infusion (0.2-0.7 mcg/kg/hr)
Study NCT02799589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Caudal anesthesia block with Ropivicaine 0.2% 1ml/kg injected into the caudal space
Study NCT01830348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DSC127
Description: DSC127 0.03%, daily topical application to diabetic foot ulcer for a period of up to 28 days or until ulcer closure, whichever is sooner
Study NCT01830348 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo vehicle gel
Study NCT02321605 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-BPS
Description: Participants are asked to write and imagine about a future in which they have reached all their goals and they have developed all their potentialities in four different domains: personal, professional, social and health domain.~They carry out the exercise in a Positive Technology System called the Book of Life, which has shown efficacy in the enhancement of positive mood (Baños, Etchemendy, Farfallini, García-Palacios, Quero \& Botella, 2014). This application looks like a personal diary, where participants can write all that they want and these essays are supported by multimedia content (pictures, songs and videos). Additionally, they can continue doing the exercise in a web platform in which they can visualize all the content they had developed previously.
Study NCT02321605 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Daily Activities
Description: Participants are asked to think and write about all that they have done the last 24 hours. They carry out the exercise in a powerpoint document, where they can record all the activities, situations and thoughts.
Study NCT04487197 — intervention group
Intervention type: PROCEDURE
Intervention: blood sample for seroepidemiological investigation
Description: blood sample for seroepidemiological investigation
Study NCT04154605 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ClariFix cryotherapy
Description: Bilateral freeze ablation of nasal tissue using the ClariFix device.
Study NCT04154605 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham ClariFix cryotherapy
Description: Bilateral sham ablation procedure using the ClariFix device.
Study NCT03345303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib Injectable Solution
Study NCT04892030 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whole Food Plant-Based Behavioral Weight Loss Treatment
Description: Over the course of 12-weeks, participants will be prescribed a non-energy-restricted whole food plant-based diet and will learn behavioral weight loss strategies through an e-learning platform. Each week, participants will also complete a 15-minute coaching call to provide positive reinforcement and problem-solving support.
Study NCT01371058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high maintenance clopidogrel
Description: clopidogrel 150 mg/d for 30 days followed by 75 mg/d for at least 1 year； aspirin 300mg/d for 1 month followed by 100mg/d chronically；
Study NCT01371058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: routine dual antiplatelet
Description: clopidogel 75mg/d for at least 1 year； aspirin 300mg/d for 1 month followed by 100mg/d chronically；
Study NCT01371058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: policosanol plus dual antiplatelet
Description: aspirin 300 mg/d for 1 month followed by 100 mg/d chronically； clopidogrel 75 mg/d for at least 1 year policosanol 40mg/d for 6 months
Study NCT02171143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2409
Description: intravenous (IV)
Study NCT02171143 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous (IV)
Study NCT03305952 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBCT
Study NCT03305952 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Study NCT00437268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzastaurin
Description: 1125 milligrams (mg) loading dose, then 500 mg orally, daily, of each 21-day cycle until progressive disease
Study NCT00437268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: 300 milligrams per square meter (mg/m\^2) intravenously on Day 1 of each 21-day cycle until progressive disease
Study NCT00437268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan
Description: 300 milligrams per square meter (mg/m\^2) intravenously on Day 1 of each 21-day cycle until progressive disease
Study NCT00437268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: 400 mg/m\^2, intravenously on Day 1, 250 mg/m\^2 on Day 8, Day 15 Cycle 1 then 250 mg/m\^2, on Day 1, 8 and 15 of each cycle, intravenously 21-day cycles until progressive disease
Study NCT00437268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab
Description: 400 mg/m\^2, intravenously on Day 1, 250 mg/m\^2 on Day 8, Day 15 Cycle 1 then 250 mg/m\^2, on Day 1, 8 and 15 of each cycle, intravenously 21-day cycles until progressive disease
Study NCT00283946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem MR
Description: Oral
Study NCT00283946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem
Description: Oral
Study NCT04176393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivosidenib
Description: subjects will receive a single dose of ivosidenib 500 mg on Day -3 (i.e., 3 days prior to the start of daily dosing) and undergo PK/PD assessments over 72 hours to evaluate drug concentrations and 2-HG levels. Following that, subjects will be treated with ivosidenib 500 mg once a day (QD) PO continuously (28-day cycles, there are no inter-cycle rest periods).
Study NCT02269696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: Intraoperative metoprolol infusion.
Study NCT02269696 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Equal of volume compared to metoprolol.
Study NCT00038948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Sirolimus, Cyclosporine A \& Tacrolimus are concentration controlled
Study NCT00038948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Study NCT00038948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine A
Study NCT02101281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhNGF 20 µg/mL
Description: 1 drop for each eye, twice daily for 28 day
Study NCT02101281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhNGF 4 µg/mL
Description: 1 drop each eye, twice daily for 28 day
Study NCT04431375 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma Exchange
Description: Plasma exchange 2 sessions alternate day followed by FMT for 7 days and Tenofovir \[antiviral\] 300mg PO once a day .
Study NCT04431375 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir
Description: Tenofovir \[antiviral\] 300mg PO once a day .
Study NCT04431375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: Tenofovir \[antiviral\] 300mg PO once a day .
Study NCT04431375 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal Mircobiota Transplantation
Description: FMT for 7 days
Study NCT06258824 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Small RNA Sequencing and Validation of candidate miRNAs
Description: Samples were prepared for small RNA sequencing using Qiagen's QIAseq small RNA Library Prep kit, quality controlled using an Agilent Bioanalyzer 2100 and sequenced on an NextSeq 500 system (Illumina, San Diego, USA) using the default single-end 75 base pair protocol to include integrated unique molecular indices (UMIs). Validation was undertaken using Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) either using target-specific stem-loop primer assays (TaqMan) or universal reverse transcription (RT) and locked nucleic acid (LNA) enhanced specific primers with SYBR green I assay detection